Introduction {#Sec1}
============

Glaucoma is a progressive optic neuropathy involving characteristic structural pathologic changes in the optic nerve head.\[[@CR1]--[@CR3]\] Reducing intraocular pressure (IOP) is presently the evidence-based, most accepted and most practiced therapeutic approach for glaucoma patients.\[[@CR4]--[@CR6]\] However, progressive loss of visual field or blindness can still occur in some glaucoma patients with controlled IOP.\[[@CR7]\] It is now recognized that the major detrimental effect of glaucoma is destruction of retinal ganglion cells (RGCs). Therefore, in the management of glaucoma, neuroprotection-based therapies are the most important.

*Erigeron breviscapus* (vant.) Hand. Mazz. (EBHM) \[Deng-zhan-hua in Chinese\] is a well known traditional Chinese medicinal plant for heart disease.\[[@CR8]\] Previous pharmacologic studies demonstrated that EBHM could stimulate the fibrinolytic and anticoagulant properties of endothelial cells, dilate blood vessels, reduce blood vessel resistance, increase blood flow, improve microcirculation, and inhibit thrombosis.\[[@CR9],[@CR10]\] Previous studies have shown that EBHM could improve the activity of cytochrome oxidase in RGCs and optic nerve axoplasmic transport in rat models of acute elevated IOP.\[[@CR11],[@CR12]\] In 2001, the China State Drug Administration approved EBHM extract for clinical use. In order to evaluate the effectiveness of EBHM extract in glaucoma patients, we conducted a prospective, randomized, double-blind clinical trial in a group of glaucoma patients with controlled IOP.

Patients and Methods {#Sec2}
====================

The study was approved by the institutional review board of Ruijin Hospital (Shanghai, China) and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients included in the study. Forty primary open-angle glaucoma (POAG) patients (25 men and 15 women) were recruited from the glaucoma specialist clinic of Ruijin Hospital between March 2002 and January 2003. One eye from each patient was chosen for the study. If both of the patient's eyes met the eligibility criteria, then one eye was chosen at random. However, patients were also included in the study if only one of their eyes met the eligibility criteria.

Patients were included in this study if they (i) met the POAG diagnosis criteria, namely, a typical glaucomatous abnormal optic nerve head associated with a typical glaucomatous visual field loss (standard automated perimetry), open-angle at gonioscopy, a presurgical IOP of \>21 mmHg with no treatment, and no clinically apparent secondary cause for their glaucoma;\[[@CR13]\] (ii) had undergone anti-glaucoma surgeries at least 3 months ago, and the IOP was ≤18 mmHg with or without medications at two measurements (10am and 3pm); (iii) had a refractive error that ranged from −6 to +3 diopters and a clear ocular media with the best-corrected visual acuity of 0.8 or better; (iv) had no clinically apparent retinal disease that might influence the visual field loss, including diabetic retinopathy, macular degeneration, and retinal vascular occlusion; (v) had stopped taking medications that may help the recovery of visual functions for at least 2 months prior, including adenosine triphosphate, inosine, red sage root, and vitamins; (vi) had no mental and nervous system diseases; and (vii) were willing to take part in this trial, and attend follow-up sessions according to the trial design.

Patients were excluded from the trial according to the following criteria: (i) history of serious systemic diseases, such as primary hypertension, heart diseases, gastric ulcer, or diabetes mellitus; (ii) inability or unwillingness to provide informed consent or abide by the study design; (iii) IOP could not be reduced to 18 mmHg or less by medications; (iv) presence of hypotony (IOP ≤6 mmHg) with thin filtering cystic bleb or bleb leakage; (v) end-stage glaucoma that could be evaluated by standard automated perimetry (reliable factor \>15%); or (vi) adverse effects due to treatment medication as assessed by a physician.

All patients' baseline data were recorded, including visual acuity, IOP, vertical cup-disk ratio (VCDR), mean defect (MD), mean sensitivity (MS), loss variance (LV), pulse, systolic blood pressure, and diastolic blood pressure. The visual field was assessed by Octopus 101 automated perimetry (Interzeg INC, Switzerland), dG2 program full threshold with Dynamic/Normal strategy. The test parameters were as follows: the background luminance was 4 apostilbs, Goldmann size III stimulus was used for the stimulus target, and the target duration time was 100 milliseconds. The crosshair in the screen provided a central fixation mark. All patients had a background illumination adaptation for 5--10 minutes before visual field examination. The visual field examinations were performed under the natural pupil size. If there was presbyopia present, it was corrected using proper convex lenses. Data analysis was derived from all 59 single data points in the central 30 degrees of the visual field. One of the following criteria was used to establish abnormal visual field results:\[[@CR13]\] (i) three adjacent points depressed by 5 dB, with one of the points depressed by at least 10 dB; (ii) two adjacent points depressed by 10 dB; or (iii) a 10 dB difference across the nasal horizontal meridian in two adjacent points. None of the points could be edge points unless immediately above or below the nasal horizontal meridian.\[[@CR14],[@CR15]\] In addition, visual field testing was only considered reliable when the reliable factor was less than 15%.

POAG was classified as early, moderate and late based on patients' visual field defects.\[[@CR16]\] Early POAG patients had an early glaucomatous visual field loss defined as an MD of ≤6 dB; moderate POAG patients had a moderate glaucomatous visual field loss defined as 12dB ≥ MD \> 6dB; and late POAG patients had a late glaucomatous visual field loss defined as an MD of \>12 dB.

Both EBHM and placebo tablets were similar looking and were provided by Xiangya Pharmaceutical Co. (Mei Er Rui, Changsha, China). The patients received two oral tablets of EBHM (containing 40 mg flavone in each tablet) or placebo, three times a day for a period of 6 months. The EBHM dose used in this study was based on that used in the treatment of cardiovascular disease. Patients were examined every 2 months after treatment commenced. The examination included the following: (i) tests for visual acuity, IOP, VCDR, visual field, pulse, systolic blood pressure, diastolic blood pressure; (ii) a complete physical examination; and (iii) screening for gastric and other adverse effects of the drug.

Statistical analyses were performed using the SAS software package (version 6.12). Student's t-test was used for numerical data and a chi-square test was used for categorical data for comparing the EBHM and placebo groups. To compare data among three or more groups, one-way ANOVA and the Kruskal-Wallis test were used. If a significant difference was detected using ANOVA, Bonferroni correction was used for the *post hoc* test. The chi-squared test was used for comparison of the visual field improvement rate between the pre- and post-treatment values. A p-value of \<0.05 was considered to be statistically significant.

Results {#Sec3}
=======

A total of 40 patients were recruited in this study, all of whom completed the trial. None of the patients had gastrointestinal discomfort, palpitation, shortness of breath, dizziness or tinnitus. [Table I](#Tab1){ref-type="fig"} shows the demographic and clinical characteristics of the patients. Baseline visual acuity, IOP, VCDR, pulse, systolic blood pressure, diastolic blood pressure, MD, MS, or LV did not differ significantly between the EBHM and placebo groups.

![Demographic and clinical characteristics of the patients^a^](40268_2012_10020075_Tab1){#Tab1}

No significant difference was found in visual acuity, IOP, VCDR, pulse, systolic blood pressure, or diastolic blood pressure between pre- and post-treatments in the EBHM and placebo groups ([tables II and III](#Tab2){ref-type="fig"}).

![Comparison of blood pressure (BP), pulse, intraocular pressure (IOP), visual acuity, and vertical cup-disk ratio (VCDR) between the pre- and the post-treatment periods in the placebo group (n = 20)^a^](40268_2012_10020075_Tab2){#Tab2}

![Comparison of blood pressure (BP), pulse, intraocular pressure (IOP), visual acuity, and vertical cup-disk ratio (VCDR) between the pre- and post-treatment periods in the *Erigeron breviscapus* (vant.) Hand. Mazz. group (n = 20)^a^](40268_2012_10020075_Tab3){#Tab3}

No significant difference was found in MD, MS, or LV between pre-treatment and after 2, 4, and 6 months of treatment in the placebo group ([table IV](#Tab4){ref-type="fig"}). No significant difference was also found in MD, MS, or LV between pre-treatment and 2 and 4 months post-treatment in the EBHM group ([table IV](#Tab4){ref-type="fig"}). However, after 6 months of EBHM treatment, the MD was significantly decreased and the MS was significantly increased compared with pre-treatment ([table IV](#Tab4){ref-type="fig"}) \[p \< 0.05\].

![Comparison of visual field indices between pre- and post-treatment periods in the placebo and *Erigeron breviscapus* (vant.) Hand. Mazz. (EBHM) groups^a^](40268_2012_10020075_Tab4){#Tab4}

In the moderate and late glaucoma patients, no significant difference was found in MD, MS, or LV between pre-treatment and after 2, 4, and 6 months of treatment in the placebo group ([table V](#Tab5){ref-type="fig"}). However, after 2, 4, and 6 months of EBHM treatment, the MD was significantly decreased and the MS was significantly increased compared with pre-treatment ([table V](#Tab5){ref-type="fig"}).

![Comparison of visual field indices of moderate and late glaucoma patients between pre- and post-treatment periods in the placebo and *Erigeron breviscapus* (vant.) Hand. Mazz. (EBHM) groups^a^](40268_2012_10020075_Tab5){#Tab5}

The differences in MD values were calculated between pre-treatment and after 2, 4, and 6 months of treatment. A decrease of \>2 dB in MD was defined as visual field improvement; a change in MD of ±2 dB was defined as no visual field change; and an increase of \>2 dB in MD was defined as the visual field retrogression. [Table VI](#Tab6){ref-type="fig"} shows the visual field improvement rate in the placebo and EBHM groups. After 6 months of treatment, the visual field improvement rate in the EBHM group (35%) was higher than that in the placebo group (15%), but did not reach statistical significance. [Table VII](#Tab7){ref-type="fig"} shows the visual field improvement rates for moderate and late glaucoma in the placebo and EBHM groups. After 6 months of treatment, the visual field improvement rate in the EBHM group (50%) was higher than that in the placebo group (13.33%), but again did not reach statistical significance (p\>0.05).

![Comparison of visual field improvement rates between the placebo and *Erigeron breviscapus* (vant.) Hand. Mazz. (EBHM) groups](40268_2012_10020075_Tab6){#Tab6}

![Comparison of visual field improvement rates of moderate and late glaucoma patients between the placebo and *Erigeron breviscapus* (vant.) Hand. Mazz. (EBHM) groups](40268_2012_10020075_Tab7){#Tab7}

Discussion {#Sec4}
==========

A major goal of glaucoma research has been to develop analogous treatment approaches to prevent the death of ganglion cells of the retina. Risk factors such as elevated IOP,\[[@CR17]--[@CR19]\] decreased neurotrophin support,\[[@CR20],[@CR21]\] glutamate-associated excitotoxicity,\[[@CR22]--[@CR24]\] hypoperfusion, and vasospasm\[[@CR25]--[@CR27]\] have been implicated in ganglion cell death in glaucoma. Neuroprotective strategies have focused on mitigating these risk factors associated with RGC loss in glaucoma.

EBHM is classified as a Chinese herbal medicine. EBHM is absorbed in the intestine through passive diffusion, and a linear relationship exists between absorption and blood concentration of EBHM over the concentration range of 50--400 μg/mL.\[[@CR28]\] After absorption, EBHM is mainly distributed in kidneys, heart, liver, and brain, and the mean retention time is 180.70±54.38 minutes.\[[@CR28]\] The main active constituents of EBHM extract include 4′-hydroscutellarein, 4′-hydrobaicalein-7-β-D-plamyagin, 4′-hydroscutellarein-7-β-D-glycuron methyl ester, pyromeconic acid, and several kinds of flavones and flavonoids.\[[@CR29]--[@CR32]\] Pharmacologic studies have demonstrated that EBHM can dilate the blood vessels, reduce blood vessel resistance, increase blood flow, improve microcirculation, and inhibit thrombosis.\[[@CR9],[@CR10]\] Although it is not known which components of EBHM are attributed to the specific effects, it has been suggested that the combined activity and a certain interdependency of several active constituents of EBHM extract are responsible for its beneficial effects.\[[@CR33]\] It is most likely that the protective and rescuing effects of EBHM extract are attributable to its ability to improve microcirculation. Bastianetto et al.\[[@CR34]\] reported that the flavonoid fraction strongly inhibited both the toxicity and the free radical accumulation induced by sodium nitroprusside and/or 3-morpholinosydnonimine. EBHM extract contains several kinds of flavones and flavonoids; therefore, it may also have the effect of inhibiting the toxicity and the free radical accumulation induced by glaucomatous neuropathy. The present study shows that the visual field indices were significantly improved (MD decrease, MS increase) after 6 months of EBHM treatment, and the improvement of visual field indices with EBHM treatment was more significant in the moderate and late glaucoma patients.

It is well known that elevated IOP is the most important factor for glaucomatous optic neuropathy; thus, lowering IOP is the most effective and commonly used therapeutic approach in glaucoma management. The present study demonstrates that the mean IOP in the two groups was less than 15 mmHg (EBHM group 14.33 mmHg, placebo group 13.71 mmHg), and there was no significant difference in IOP between the two groups during the treatment period. Therefore, it has been shown that EBHM is effective in rescuing glaucomatous optic neuropathy while maintaining IOP at normal or below normal levels.

The present study also shows that the visual field improvement rate in the EBHM group was higher than that in the placebo group after 6 months of treatment; however, it did not reach statistical significance, which may be attributed to the small number of patients. No treatment-related adverse effects were observed.

In summary, the results of this study suggested that EBHM extract may have a partially protective effect on the visual field of glaucoma patients with controlled IOP. Further studies are needed to determine the safety and effectiveness of long-term EBHM treatment.
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